Mizoribine improves renal tubulointerstitial fibrosis in unilateral ureteral obstruction (UUO)-treated rat by inhibiting the infiltration of macrophages and the expression of α-smooth muscle actin

Journal of Urology

Volumn 158, Issue 6, 1997, Pages 2316-2322

  Sakai, Tsuyoshi ^a   Kawamura, Tetsuya ^b   Shirasawa, Takuji ^b  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b NONE

Author keywords

Immunohistochemistry; Macrophage; Mizoribine; Tubulointerstitial fibrosis; Unilateral ureteral obstruction; SMA

Indexed keywords

ALPHA ACTIN; MIZORIBINE; PREDNISOLONE SODIUM SUCCINATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INTERSTITIAL NEPHRITIS; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY FIBROSIS; MACROPHAGE; MYOFIBROBLAST; NONHUMAN; OBSTRUCTIVE UROPATHY; PRIORITY JOURNAL; RAT; URETER OBSTRUCTION;

EID: 0030825940     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)68242-9     Document Type: Article

References (23)

1. Kuncio, G. S., Neilson, E. G. and Haverty, T.: Mechanisms of tubulointerstitial fibrosis. Kidney Int., 39: 550, 1991.
2. Pichler, R., Giachelli, C. M., Lombardi, D., Pippin, J., Gordon, K., Alpers, C. E., Schwart, S. M. and Johnson, R. J.: Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am. J. Pathol., 144: 915, 1994.
3. Muller, G. A., Markovic-Lipkovski, J., Frank, J. and Rodemann, H. P.: The role of interstitial cells in the progression of renal diseases. J. Am. Soc. Nephrol., S198, 1992.
4. Diamond, J. R., van Goor, H., Ding, G. and Engelmyer, E.: Myofibroblasts in experimental hydronephrosis. Am. J. Pathol., 146: 121, 1995.
5. Wright, E. J., McCaffrey, T. A., Robertson, A. P., Vaughan, D. D. Jr., and Felsen, D.: Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta. Lab. Invest., 74: 528, 1996.
6. Klahr, S., Harris, K. and Purkerson, M. L.: Effects of obstruction on renal functions. Pediatr. Nephrol., 2: 34, 1988.
7. Klahr, S.: New insights into the consequences and the mechanisms of renal impairment in obstructive nephropathy. Am. J. Kidney Dis., 18: 689, 1991.
8. Sharma, A. K., Mauer, S. M., Kim, Y. and Michael, A. F.: Interstitial fibrosis in obstructive nepphropathy. Kid. Int., 44: 774, 1993.
9. Schreiner, G. F., Harris, K. P., Purkerson, M. L. and Klahr, S.: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney. Kidney Int., 34: 487, 1988.
10. Klahr, S. and Pukerson, M. L.: The pathophysiology of obstructive nephropathy: The role of vasoactive compounds in the hemodynamic and structural abnormalities of the obstructed kidney. Am. J. Kidney Dis., 23: 219, 1994.
11. Inou, T., Kusaba, R., Takahashi, I., Sugimoto, H., Kuzuhara, K., Yamada, Y., Yamauchi, J. and Otsubo, O.: Clinical trial of Bredinin in renal transplantation. Transplant Proc., 12: 526, 1980.
12. Hirohata, S. and Yanagida, T.: Inhibition of expression of cyclin A in human B cells by an immunosuppressant mizoribine. J. Immunol., 155: 5175, 1995.
13. Turka, L. A., Dayton, J., Sinclair, G., Thompson, C. B. and Mitchell, B. S.: Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J. Clin. Invest., 87: 940, 1991.
14. Thomson, A. W., Woo, J., Yao, G. Z., Todo, S., Starzl, T. E. and Zeevi, A.: Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures. Transpl. Immunol., 1: 146, 1993.
15. Okamoto, K., Ito, M. and Suzuki, Y.: Studies on antinephritic effect of mizoribine (p-INN, Bredinin), a new immunosuppressive agent, and azathioprine effect on the nephrotic type of anti-GBM nephritis in rats. Japan J. Pharmacol., 33: 541, 1983.
16. Okubo, M., Chen, X. M., Kamata, K., Masaki, Y. and Uchiyama, T.: Suppressive effect of mizoribine on humoral antibody production in DBA/2 mice. Transpl., 41: 495, 1996.
17. Ishidoya, S., Morrissey, J., McCracken, R., Reyes, A. and Klahr, S.: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int., 47: 1285, 1995.
18. Hanke, H., Hassenstein, S., Ulmer, A., Kamenz, J., Oberhoff, M., Haase, K. K., Baumbach, A., Gown, A. M. and Karsch, K. R.: Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. Eur. Heart J., 15: 691, 1994.
19. Kliem, V., Johnson, R. J., Alpers, C. E., Yoshimura, A., Couser, W. G., Koch, K. M. and Floege, J.: Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int., 49: 666, 1996.
20. Turka, L. A., Dayton, J., Sinclair, G., Thompson, C. B. and Mitchell, B. S.: Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J. Clin. Invest., 87: 940, 1991.
21. Dayton, J. S., Turka, L. A., Thompson, C. B. and Mitchell, B. S.: Comparison of the effects of mizoribine with those of azathioprine, 6- mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol. Pharmacol., 41: 671, 1992.
22. Brinkmann, V. and Kristofic, C.: Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. J. Immunol., 155: 3322, 1995.
23. Amano, Y., Lee, S. W. and Allison, A. C.: Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol. Pharmacol., 43: 176, 1993.